|Day Low/High||40.75 / 41.33|
|52 Wk Low/High||37.43 / 50.65|
Stocks rise on Friday, putting the Dow Jones Industrial Average one step closer to the psychologically important 20,000 level.
U.S. stock futures are mixed while the dollar surges as global markets adjust to higher U.S. interest rates; Facebook plans to fact-check its news; Adobe's earnings top forecasts.
European stocks are set to book another solid weekly advance amid global market adjustments to the new Fed outlook.
Actelion stocks surged higher in Zurich amid speculation that France's Sanofi may make a formal approach for the Swiss biotech.
Actelion was too pricey. Now J&J is looking for another acquisition.
Jim Cramer comments on Johnson & Johnson's move to abandon merger talks with Actelion.
U.S. stock futures are mixed ahead of a decision on interest rates and fresh economic forecasts from the Fed; tech giants meet with Donald Trump; IBM's Rometty promises jobs.
Actelion confirms the end of talks with J&J over a $27 billion takeover, and market focus shifts to France's Sanofi.
European stocks are set to open lower Wednesday ahead of the Fed's final policy meeting of 2016.
U.S. stock futures trade flat following another record close for the Dow; Amazon reportedly envisions opening 2,000 brick-and-mortar grocery stores; Apple Watch sales set a record, Apple CEO says.
European markets are set for a positive open Tuesday after Asia traders booked their best single-day gains in two weeks.
Actelion shares are on the rise again on reports of a potential counter-bid from France's Sanofi.
Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the initiation of the ICARIA-MM Phase III trial of isatuximab, an investigational anti-CD38 monoclonal antibody being studied for the...
Actelion shares traded sharply lower Tuesday following reports it's looking at strategies that would keep it independent from a $17 billion approach from Johnson & Johnson.
The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.
Wall Street runs at two speeds as a rally in financials sent the Dow Jones Industrial Average to close at records, while a selloff in tech sank the Nasdaq.
Wall Street remains divided on Thursday as investors try to gauge the types of policies president-elect Donald Trump could enact.
MannKind bulls -- the rainbow-hued unicorns of the investment world -- believe the company's marketing efforts will succeed. They're wrong.
A sale or spinoff of this business will likely get the attention of competitors that want to increase their over-the-counter product units.
Wall Street runs at two speeds on Thursday with the Dow Jones Industrial Average setting a record high and the S&P 500 and Nasdaq slipping.
Stock futures move higher on Thursday with the Dow Jones Industrial Average set to open at a high.
As we all know, the stock market and the economy abhor uncertainty.
Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.
The threat of a government clampdown on drug prices is off the table with Clinton's defeat, while wider support for defensive stocks helped push pharmaceuticals higher.
Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.
The biotech company cancelled its conference appearance and took its time filing its Form 10-Q with the Securities and Exchange Commission.
Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the first patient has been enrolled and received an infusion in a pivotal Phase 3 clinical trial named COMET for the...
Tech giants, Big Pharma and insurers are all angling to profit from the $3 trillion-plus U.S. healthcare market.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.